APOE 3/4 means you carry two different versions of the APOE gene: one copy of the E3 variant (the most common) and one copy of the E4 variant (linked to higher health risks). You inherited one from each biological parent. This combination places you in a middle-risk category for Alzheimer’s disease and cardiovascular issues, carrying roughly two to three times the Alzheimer’s risk of someone with the most common genotype (3/3).
How the APOE Gene Works
The APOE gene tells your body how to make a protein that shuttles cholesterol and other fats through your bloodstream. Everyone carries two copies of this gene, one from each parent, and each copy comes in one of three versions: E2, E3, or E4. That creates six possible combinations: 2/2, 2/3, 2/4, 3/3, 3/4, and 4/4.
E3 is the most common version worldwide and is generally considered the neutral baseline. E2 is associated with lower cardiovascular risk. E4 is the version that raises red flags, because the protein it produces is structurally less stable than the others. This instability changes how the protein handles fats and how well it supports certain cleanup processes in the brain.
What This Means for Alzheimer’s Risk
Having one copy of E4 (as in a 3/4 genotype) doubles or triples your risk of developing late-onset Alzheimer’s disease compared to someone with two copies of E3. That said, the actual risk depends heavily on sex and ancestry. Women of European descent between ages 50 and 80 who carry one E4 copy face three to four times the risk of their E3/E3 counterparts, while men with the same genotype show only a marginally increased risk. In Japanese populations, a single E4 copy is associated with roughly five times the risk.
People with the E4 variant also tend to develop symptoms earlier. On average, each copy of E4 shifts the onset of Alzheimer’s forward by 10 to 15 years compared to those without it. For a 3/4 carrier, that shift comes from the single E4 copy.
It’s important to keep these numbers in perspective. The E4 allele is neither necessary nor sufficient to cause Alzheimer’s. Many people with APOE 3/4 never develop the disease, and many people with 3/3 do. The gene shifts probability, not destiny.
Why E4 Affects the Brain
One of the hallmarks of Alzheimer’s is the buildup of sticky protein fragments called amyloid-beta in the brain. Your brain constantly produces these fragments and constantly clears them out. The E4 version of the APOE protein is worse at facilitating that cleanup. It’s more compact and unstable than E3, which impairs its ability to bind fats and support the cells responsible for clearing amyloid debris.
The immune cells in your brain that normally act as garbage collectors become less effective in the presence of E4. They accumulate fat, produce more inflammatory signals, and lose some of their ability to break down waste. At the same time, E4 may actually increase the production of amyloid-beta. The result is a slower drain and a faster faucet, which over decades can tip the balance toward buildup.
Effects on Cholesterol and Heart Health
The APOE gene doesn’t only matter for your brain. Because the protein it makes is directly involved in transporting fats through your blood, different variants produce different cholesterol profiles. The E4 protein preferentially binds to larger, triglyceride-rich particles (VLDL and LDL) rather than the smaller, more protective HDL particles that E3 and E2 favor. This creates a more cholesterol-heavy distribution in your bloodstream.
E4 carriers are predisposed to higher cholesterol levels and a greater risk of atherosclerosis, the buildup of fatty plaques in arteries. E2 carriers, by contrast, have roughly 20% lower cardiovascular risk than E3 carriers. As a 3/4 carrier, your lipid profile may lean toward higher LDL cholesterol, which makes monitoring and managing cholesterol through diet, exercise, and (if needed) medication more relevant for you than for the average person.
How Exercise and Lifestyle Modify Your Risk
One of the more encouraging findings for E4 carriers is that lifestyle factors appear to have an outsized positive effect. Research using animal models of different APOE genotypes found that regular aerobic exercise reduced LDL cholesterol, slowed age-related fat accumulation, and attenuated weight gain, with effects that varied by sex and genotype. In females, the E4/E4 genotype showed the greatest exercise-driven reduction in weight gain, and LDL levels dropped in proportion to the number of E4 copies. In males, the 3/4 genotype showed the biggest reduction in age-related fat and lean mass accumulation with exercise.
Human studies echo this pattern. There is evidence that exercise helps preserve cognitive function in E4 carriers more effectively than in non-carriers, suggesting that E4 carriers may actually be more responsive to the brain-protective effects of physical activity. While no single lifestyle change eliminates genetic risk, the combination of regular exercise, a heart-healthy diet, and active cholesterol management appears to be especially impactful for people with your genotype.
What This Means for Medical Treatment
A new class of Alzheimer’s drugs works by clearing amyloid-beta from the brain. Your APOE status matters here because E4 carriers face a higher risk of a side effect called ARIA, which involves temporary swelling or small bleeds in the brain detectable on MRI. For people with one E4 copy (like 3/4 carriers), this risk is elevated but manageable with monitoring. The risk is significantly higher for people homozygous for E4 (4/4), where the decision to start treatment becomes more complex. If you ever consider these therapies, your doctor will factor your APOE status into the risk-benefit calculation.
Should You Get Tested?
If you’re reading this, you may have already received your APOE result through a direct-to-consumer test or a clinical workup. Professional guidelines from the American College of Medical Genetics and the National Society of Genetic Counselors do not recommend routine APOE testing for predicting Alzheimer’s risk in the general population. The primary reasons: the test has limited predictive value for any individual, and there is no guaranteed way to prevent the disease. The E4 allele shifts risk, but it doesn’t confirm or rule out a diagnosis.
That said, knowing your genotype can motivate meaningful action. Cardiovascular risk management, regular exercise, cognitive engagement, and awareness of early symptoms are all practical steps that benefit E4 carriers. If you already have your result, the most useful thing you can do is treat it as a reason to invest in the health habits that lower both heart disease and dementia risk, not as a prediction of what will happen to you.
How Common Is APOE 3/4?
The 3/4 genotype is one of the more common APOE combinations globally, though its frequency varies by population. The E4 allele itself is most prevalent in Central African populations (reaching 30 to 40% in some groups), parts of Oceania, and certain indigenous populations in Mexico. In European populations, E4 allele frequencies are moderate, and in Southern Europe they tend to be lower than in Northern Europe. Studies of people who reach extreme old age consistently find that E4 carriers, including those with 3/4, are underrepresented, while the E2/E3 genotype is enriched. This doesn’t mean 3/4 carriers can’t live long lives, but it reinforces that the E4 allele is one factor working against longevity at a population level.